Skip to main content

Treatment Clinical Trials for Pancreatic Cancer

Review the pancreatic cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 213

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer or Metastatic Melanoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for the Treatment of Pancreatic Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Intra-Tumoral Mitazalimab with Irreversible Electroporation for the Treatment of Locally Advanced Pancreas Cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Stereotactic Body Radiation Therapy in Combination with TTI-101 for the Treatment of Borderline Resectable and Locally Advanced Pancreatic Ductal Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Pooled Mutant KRAS-Targeted Long Peptide Vaccine with Balstilimab and Botensilimab for the Treatment of Patients with Stage IV Non-MSI-H/dMMR Colorectal Cancer and Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T-cells for the Treatment of Refractory Pancreatic Ductal Adenocarcinoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Zunsemetinib with mFOLFIRINOX for the Treatment of Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Personalized Peptide Vaccine in Treating Patients with Advanced Pancreatic Cancer or Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Gallium Ga 68-DOTA-5G and Lutetium Lu 177-DOTA-ABM-5G in Diagnosing and Treating Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Gemcitabine and Leflunomide in Patients with Advanced Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
PRMT5 Inhibition with BMS-986504 and PARP Inhibition with Olaparib for the Treatment of Advanced and Metastatic Solid Tumors with MTAP Loss
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Status: Active
Location: 4 locations
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas